Cenderitide
- Generic Name
- Cenderitide
- Drug Type
- Biotech
- CAS Number
- 507289-11-4
- Unique Ingredient Identifier
- 9NKZ9LYZ06
- Background
Cenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall.
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
- Conditions
- Left Ventricular Assist DeviceNatriuretic PeptideHeart Failure
- Interventions
- Other: Placebo
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT03091998
Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment
- Conditions
- Heart FailureRenal Insufficiency
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Capricor Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02603614
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
Safety Study of Cenderitide in Stable Chronic Heart Failure
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Capricor Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02359227
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function
- Conditions
- ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT02071602
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 14
- Registration Number
- NCT01750905
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Effects of Chimeric Natriuretic Peptide Versus Placebo in Stable Heart Failure and Moderate Renal Dysfunction
- Conditions
- Heart FailureRenal Insufficiency
- Interventions
- Drug: 5% Dextrose in Water
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- John A. Schirger
- Registration Number
- NCT01407900
PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients
- Conditions
- Heart FailureADHFChronic Heart FailureCHF
- Interventions
- Other: Placebo
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- Nile Therapeutics
- Target Recruit Count
- 58
- Registration Number
- NCT01316432
- Locations
- 🇺🇸
Analab Clinical Research, Inc., Lenexa, Kansas, United States
🇺🇸Hennepin County Medical Center, Minneapolis, Minnesota, United States
🇺🇸Orange County Research Center, Tustin, California, United States
Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- Nile Therapeutics
- Target Recruit Count
- 77
- Registration Number
- NCT00839007
Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)
- Conditions
- Acute Decompensated Heart Failure
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Nile Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT00699712
- Locations
- 🇷🇺
Russian Academy of Medical Sciences, Moscow, Russia, Russian Federation
CD-NP in Subjects With Stable Chronic Heart Failure
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 19
- Registration Number
- NCT00620308
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.